By: IPP Bureau
Last updated : August 16, 2025 8:20 am
The inspection concluded with NIL observations
Zydus announced that the USFDA has completed a Pre-Approval Inspection (PAI) and general cGMP inspection at its formulation manufacturing plant in SEZ II, Ahmedabad. The inspection, conducted from 11 to 13 August 2025 for three products, concluded with no observations.
The inspection concluded with NIL observations.